Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Mersana Therapeutics (MRSN) stocks in Canada

Learn how to easily invest in Mersana Therapeutics stocks.

Mersana Therapeutics is a biotechnology business based in the US. Mersana Therapeutics stocks (MRSN.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $12.85 – an increase of 17.11% over the previous week. Mersana Therapeutics employs 169 staff and has a trailing 12-month revenue of around $2.1 million.

How to buy stocks in Mersana Therapeutics

  1. Compare stock trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – MRSN – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of stocks with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Mersana Therapeutics stock price (NASDAQ:MRSN)

Use our graph to track the performance of MRSN stocks over time.

Mersana Therapeutics shares at a glance

Information last updated 2022-05-19.
Latest market close$3.49
52-week range$2.68 - $15.34
50-day moving average $3.92
200-day moving average $6.90
Wall St. target price$18.00
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-2.49

Compare stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

1 - 6 of 6
Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Young investors 18 to 24 can get free online trades and a $0 annual account fee. Conditions apply.
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get $500 in commission free trades when you fund your account with a minimum of $10,000. Conditions apply. Ends August 31st, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Mersana Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Mersana Therapeutics price performance over time

Historical closes compared with the close of $3.49 from 2022-05-20

1 week (2022-05-12) 22.89%
1 month (2022-04-22) -9.35%
3 months (2022-02-18) N/A
6 months (2021-11-22) -54.08%
1 year (2021-05-21) -75.16%
2 years (2020-05-22) -64.75%
3 years (2019-05-22) 4.94
5 years (2017-05-18) N/A

Mersana Therapeutics financials

Revenue TTM $2.1 million
Gross profit TTM $-131,970,000
Return on assets TTM -44.65%
Return on equity TTM -107.91%
Profit margin 0%
Book value $1.61
Market capitalisation $334.6 million

TTM: trailing 12 months

Mersana Therapeutics share dividends

We're not expecting Mersana Therapeutics to pay a dividend over the next 12 months.

Mersana Therapeutics share price volatility

Over the last 12 months, Mersana Therapeutics's shares have ranged in value from as little as $2.68 up to $15.34. A popular way to gauge a stock's volatility is its "beta".

MRSN.US volatility(beta: 2.35)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Mersana Therapeutics's is 2.3477. This would suggest that Mersana Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Mersana Therapeutics overview

Mersana Therapeutics, Inc. , a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site